Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

View:
Post by infinity888 on Jul 14, 2021 10:36am

Level 2

Level 2 Quote

Market Depth Orders/Shares Bid Price   Ask Price Shares/Orders Market Depth
  98 / 10,926,000 0.02   0.03 2,361,000 / 41  
  30 / 1,873,000 0.015   0.035 2,067,000 / 40  
  16 / 920,000 0.01   0.04 2,800,000 / 50  
  12 / 2,729,000 0.005   0.045 830,000 / 22  
  -- --   0.05 1,195,000 / 27  
  -- --   0.055 983,000 / 19  
  -- --   0.06 1,230,000 / 18  
  -- --   0.065 1,689,000 / 17  
  -- --   0.07 1,979,000 / 22  
  -- --   0.075 1,669,000 / 13  
Comment by mavericks2020 on Jul 14, 2021 10:49am
over 0.04 the shorter are very busy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities